PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR). LPI (LP Information)' newest research report, the “Influenza Diagnostics Industry Forecast” looks at past sales and reviews total world Influenza Diagnostics sales in 2022, providing a comprehensive analysis by region and market sector of projected Influenza Diagnostics sales for 2023 through 2029. With Influenza Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Influenza Diagnostics industry. This Insight Report provides a comprehensive analysis of the global Influenza Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Influenza Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Influenza Diagnostics market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Influenza Diagnostics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Influenza Diagnostics. The global Influenza Diagnostics market size is projected to grow from US$ 2284.7 million in 2022 to US$ 3558.7 million in 2029; it is expected to grow at a CAGR of 6.5% from 2023 to 2029. North America is the largest consumption place, with a consumption marker share nearly 53%. Following North America, Europe is the second largest consumption place with the consumption market share of 25%. The main manufacturers are BD, Abbott (Include Alere), Roche, SIEMENS, Analytik Jena, Quidel, Thermo Fisher, Meridian Bioscience, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific etc. BD is the largest manufacturer with about 19% market share. This report presents a comprehensive overview, market shares, and growth opportunities of Influenza Diagnostics market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type RIDT RT-PCR Cell Culture Others Segmentation by application Hospitals POCT Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. BD Abbott (Include Alere) Roche SIEMENS Analytik Jena Quidel Thermo Fisher Meridian Bioscience BioMerieux Sekisui Diagnostics Response Biomedical SA Scientific